US Bancorp’s Stemline Therapeutics, Inc. STML Stock Holding History

US Bancorp’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-500	Closed	-$2K	–	3980
2020 Q1	$2K	Buy	+500	New	+$3.24K	﹤0.01%	3525

US Bancorp's STML Position: Q2 2020 in Review

US Bancorp sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 500 shares — an estimated $2K sold.

US Bancorp first reported a position in STML in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

US Bancorp reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
US Bancorp sold 500 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $2K.
US Bancorp first reported a position in Stemline Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
US Bancorp's Stemline Therapeutics, Inc. position peaked at $2K in Q1 2020.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on US Bancorp's 13F filing for Q2 2020, filed 7 Aug 2020.